Low‐n oligomers as therapeutic targets of Alzheimer’s disease

Ono, Kenjiro; Yamada, Masahito

doi:10.1111/j.1471-4159.2011.07187.x

Cited by 76

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Low‐n oligomers as therapeutic targets of Alzheimer’s disease

Ono, Kenjiro, Yamada, Masahito·2011·Journal of Neurochemistry

DOI 10.1111/j.1471-4159.2011.07187.x

Open this paper in CoChat — free account

Abstract

J. Neurochem. (2011) 117, 19–28. The pathogenesis of Alzheimer’s disease involves the progressive accumulation of amyloid β‐protein (Aβ). Recent studies using synthetic Aβ peptides, a cell culture model, Aβ precursor protein transgenic mice models suggest that pre‐fibrillar forms of Aβ are more deleterious than extracellular fibril forms. Recent findings obtained using synthetic Aβ peptides and human samples indicated that low‐n oligomers (from dimers to octamers) may be proximate toxins for neuron and synapse. Here, we review the recent studies on the soluble oligomers, especially low‐n oligomers in Alzheimer’s disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1471-4159.2011.07187.x

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Current therapeutic interventions intended to reduce amyloid-β plaques may clear amyloid fibrils and largely inert plaques but may only partially address the specific neurotoxic effects of amyloid-β oligomers.
“A potential weakness of current therapeutic interventions intended to reduce amyloid-β plaques in the brain is that although these approaches may clear amyloid fibrils and the largely inert plaques, they may only partially address the specific neurotoxic effects of amyloid-β oligomers [30]”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [30]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 2×
“…Tg2576 mice show impaired performance in a hippocampal-dependent contextual fear conditioning assay, decreased spine density in the dentate gyrus, and impairment of LTP at ages long before the first apparent detection of Ab dodecamer (Dineley et al. 2002; Jacobsen et al. 2006; Lesne et al. 2006).”
BackgroundMethod
Retracted
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability
Dahlgren, K. N., Manelli, A. M., Stine, W. B., Baker, L. K., Krafft, G. A., & LaDu, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201750200 · Cited by 1,452
Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447
Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models
Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G.-Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R. C., Nicoll, R. A., & Mucke, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3228 · Cited by 1,123
Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs.
Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M., Henschen, A., Yates, J., Cotman, C., & Glabe, C. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48529-8 · Cited by 1,014
Metal-Protein Attenuation With Iodochlorhydroxyquin (Clioquinol) Targeting Aβ Amyloid Deposition and Toxicity in Alzheimer Disease: A Pilot Phase 2 Clinical Trial
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988
The Levels of Soluble versus Insoluble Brain Aβ Distinguish Alzheimer's Disease from Normal and Pathologic Aging
Wang, J., Dickson, D. W., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7085 · Cited by 567
Aging renders the brain vulnerable to amyloid β-protein neurotoxicity
Guela, C., Wu, C.-K., Saroff, D., Lorenzo, A., Yuan, M., & Yankner, B. A. (1998) · Nature Medicine · doi:10.1038/nm0798-827 · Cited by 520
Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo
Klyubin, I., Walsh, D. M., Lemere, C. A., Cullen, W. K., Shankar, G. M., Betts, V., Spooner, E. T., Jiang, L., Anwyl, R., Selkoe, D. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1234 · Cited by 489
A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo
Tomiyama, T., Matsuyama, S., Iso, H., Umeda, T., Takuma, H., Ohnishi, K., Ishibashi, K., Teraoka, R., Sakama, N., Yamashita, T., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5825-09.2010 · Cited by 396
Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease
Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507892200 · Cited by 379
Clusterin (apoJ) Alters the Aggregation of Amyloid β-Peptide (Aβ1-42) and Forms Slowly Sedimenting Aβ Complexes That Cause Oxidative Stress
Oda, T., Wals, P., Osterburg, H. H., Johnson, S. A., Pasinetti, G. M., Morgan, T. E., Rozovsky, I., Stine, W. B., Snyder, S. W., Holzman, T. F., et al. (1995) · Experimental Neurology · doi:10.1006/exnr.1995.1080 · Cited by 352
Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization
Klyubin, I., Betts, V., Welzel, A. T., Blennow, K., Zetterberg, H., Wallin, A., Lemere, C. A., Cullen, W. K., Peng, Y., Wisniewski, T., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5161-07.2008 · Cited by 321
Metal complexing agents as therapies for Alzheimer’s disease
Bush, A. I. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00120-3 · Cited by 310
Accelerated Plaque Accumulation, Associative Learning Deficits, and Up-regulation of α7 Nicotinic Receptor Protein in Transgenic Mice Co-expressing Mutant Human Presenilin 1 and Amyloid Precursor Proteins
Dineley, K. T., Xia, X., Bui, D., Sweatt, J. D., & Zheng, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200164200 · Cited by 212
Appearance of Sodium Dodecyl Sulfate-Stable Amyloid β-Protein (Aβ) Dimer in the Cortex During Aging
Enya, M., Morishima-Kawashima, M., Yoshimura, M., Shinkai, Y., Kusui, K., Khan, K., Games, D., Schenk, D., Sugihara, S., Yamaguchi, H., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65273-x · Cited by 111
Aβ oligomers inhibit synapse remodelling necessary for memory consolidation
Freir, D. B., Fedriani, R., Scully, D., Smith, I. M., Selkoe, D. J., Walsh, D. M., & Regan, C. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.01.001 · Cited by 85

Flagged first, then by citations

Research works printed but not linked: 77

10.1016/j.neuron.2008.06.018 · DOI · Paper page
10.1097/jcp.0b013e318160862c · DOI
10.1016/S0140-6736(06)69113-7 · DOI · Paper page
10.1016/0197-4580(92)90065-6 · DOI
10.1016/S0006-291X(86)80241-8 · DOI
10.1038/6374 · DOI · Paper page
10.1074/jbc.M701078200 · DOI
10.1073/pnas.97.2.571 · DOI
10.1016/0197-4580(95)00013-5 · DOI · Paper page
10.1136/bmj.314.7086.993j · DOI
10.1007/s12035-010-8137-1 · DOI
Funato H., 1998, Quantitation of amyloid β‐protein (Aβ) in the cortex during aging and in Alzheimer’s disease, Am. J. Pathol., 152, 1633
10.1016/S0002-9440(10)65094-8 · DOI
10.1016/j.neurobiolaging.2006.02.015 · DOI
10.1038/357500a0 · DOI
10.2353/ajpath.2009.090417 · DOI
10.1111/j.1755-5949.2010.00147.x · DOI · Paper page
10.1126/science.1072994 · DOI · Paper page
10.1523/JNEUROSCI.19-20-08876.1999 · DOI · Paper page
10.1002/(SICI)1097-4547(20000515)60:4<490::AID-JNR7>3.0.CO;2-9 · DOI
10.1021/bi061540x · DOI
10.1093/brain/awn174 · DOI
10.1074/jbc.271.37.22908 · DOI
Ikeda T., 2010, Cerebrospinal fluid from Alzheimer’s disease patients promotes amyloid β‐protein oligomerization, J. Alzheimers Dis., 21, 81, 10.3233/JAD-2010-100075 · DOI
10.1073/pnas.0600948103 · DOI · Paper page
10.1021/bi00069a001 · DOI · Paper page
10.1056/NEJM198604103141506 · DOI · Paper page
10.1002/jnr.10328 · DOI
10.1073/pnas.84.19.6953 · DOI
10.1016/S0166-2236(00)01749-5 · DOI · Paper page
10.1016/j.neurobiolaging.2004.02.010 · DOI
10.1111/j.1460-9568.2004.03389.x · DOI
10.1210/mend-4-10-1580 · DOI
10.1073/pnas.95.11.6448 · DOI · Paper page
10.1016/S1474-4422(08)70167-4 · DOI · Paper page
10.7326/0003-4819-118-4-199302150-00028 · DOI
10.1016/j.neuron.2009.05.012 · DOI · Paper page
10.1523/JNEUROSCI.21-21-08370.2001 · DOI · Paper page
10.1016/S0002-9440(10)65184-X · DOI · Paper page
10.1093/brain/awq065 · DOI · Paper page
10.1038/nm1423 · DOI
10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M · DOI
10.1152/ajpendo.00082.2006 · DOI
10.1074/jbc.274.10.6483 · DOI · Paper page
10.1021/bi981843u · DOI
10.1523/JNEUROSCI.20-11-04050.2000 · DOI · Paper page
10.1046/j.1471-4159.2003.01976.x · DOI
10.1016/j.bbadis.2004.06.008 · DOI
10.1002/jnr.20025 · DOI · Paper page
10.2174/138161206778793010 · DOI
10.1074/jbc.M806154200 · DOI
10.1073/pnas.0905127106 · DOI
10.1074/jbc.M109.086496 · DOI
Orgogozo J. M., 1997, Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area, Rev. Neurol. (Paris), 153, 185
10.1016/0006-8993(91)91553-D · DOI
10.1074/jbc.270.16.9564 · DOI
10.2174/1567205053585882 · DOI
10.1074/jbc.271.34.20631 · DOI
10.1074/jbc.R800036200 · DOI
10.1002/ana.20524 · DOI · Paper page
10.1002/ana.410300410 · DOI · Paper page
10.1113/jphysiol.2005.103754 · DOI · Paper page
10.1212/01.WNL.0000031421.50369.E7 · DOI
10.2174/157488906775245354 · DOI
10.1111/j.1471-4159.1993.tb09841.x · DOI · Paper page
10.1021/bi001048s · DOI · Paper page
10.1038/416535a · DOI · Paper page
10.1523/JNEUROSCI.4391-04.2005 · DOI
10.1016/S0006-8993(01)03058-X · DOI · Paper page
10.1523/JNEUROSCI.0364-08.2008 · DOI
Wang J., 2010, Grape derived polyphenols attenuate tau neuropathology in a mouse model of Alzheimer’s disease, J. Alzheimers Dis., 22, 653, 10.3233/JAD-2010-101074 · DOI
10.1523/JNEUROSCI.22-05-01858.2002 · DOI
10.1358/dot.2006.42.5.973584 · DOI
10.1073/pnas.0402147101 · DOI
10.1001/archneurol.2008.565 · DOI
10.2174/138161208786404137 · DOI
10.1074/jbc.M404751200 · DOI · Paper page

Sorted by citations

Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia
Ferrer, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.005 · Cited by 174
Alzheimer’s disease as oligomeropathy
Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129
Self-citation
Hippocampal GABAergic Neurons are Susceptible to Amyloid-β Toxicity in vitro and are Decreased in Number in the Alzheimer's Disease TgCRND8 Mouse Model
Krantic, S., Isorce, N., Mechawar, N., Davoli, M. A., Vignault, E., Albuquerque, M., Chabot, J.-G., Moyse, E., Chauvin, J.-P., Aubert, I., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110830 · Cited by 78
Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases
Lizama, B. N., Kahle, J., Catalano, S. M., Caggiano, A. O., Grundman, M., & Hamby, M. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076251 · Cited by 54

Authors: Ono, K., & Yamada, M.
Venue: Journal of Neurochemistry
Publisher: Wiley
Published: 2011-02-09
Volume: 117
Issue: 1
Pages: 19-28
ISSN: 0022-3042
1471-4159
DOI: 10.1111/j.1471-4159.2011.07187.x
Cited by: 76
References: 23
Language: en
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Low‐n oligomers as therapeutic targets of Alzheimer’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks